Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma
Sponsor: Chugai Pharmaceutical
Summary
This is a multicenter, open-label, dose-escalation study designed to determine the maximum tolerated dose (MTD) by evaluating dose-limiting toxicities (DLTs) and to evaluate the safety, tolerability, pharmacokinetics, anti-tumor effect, and biomarkers of ERY974 in combination with atezolizumab and bevacizumab following premedication with tocilizumab in patients with locally advanced or metastatic HCC.
Official title: A PHASE I STUDY OF ERY974 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC HEPATOCELLULAR CARCINOMA
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
179
Start Date
2021-06-01
Completion Date
2025-12-31
Last Updated
2024-09-05
Healthy Volunteers
No
Conditions
Interventions
ERY974
ERY974 vial
Tocilicumab
Tocilizumab vial
Atezolizumab
Atezolizumab vial
Bevacizumab
Bevacizumab vial
Locations (11)
Chiba University Hospital
Chiba, Chiba, Japan
National Cancer Center Hospital East
Kashiwa, Chiba, Japan
Kanagawa Cancer Center
Yokohama, Kanagawa, Japan
Kindai University Hospital
Sayama, Osaka, Japan
National Cancer Center Hospital
Chuo Ku, Tokyo, Japan
Kaohsiung Chang Gung Memorial Hospital
Kaohsiung City, Taiwan
Taichung Veterans General Hospital
Taichung, Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan
Chi Mei Medical Center
Tainan, Taiwan
National Taiwan University Hospital
Taipei, Taiwan
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan